This post was originally published on this site

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there a number of risks to biotech over the next 1-2 years out of Washington. ReadRead More »

The post Five Macro Risks To Biotech Coming Out of Washington appeared first on Atlas Venture.